279 related articles for article (PubMed ID: 37529238)
21. Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru.
Montero S; Urrunaga-Pastor D; Soto-Becerra P; Cvetkovic-Vega A; Guillermo-Roman M; Figueroa-Montes L; Sagástegui AA; Alvizuri-Pastor S; Contreras-Macazana RM; Apolaya-Segura M; Díaz-Vélez C; Maguiña JL
Vaccine X; 2023 Aug; 14():100311. PubMed ID: 37207103
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
Moghnieh R; Mekdashi R; El-Hassan S; Abdallah D; Jisr T; Bader M; Jizi I; Sayegh MH; Rahman Bizri A
Vaccine; 2021 Nov; 39(46):6713-6719. PubMed ID: 34656379
[TBL] [Abstract][Full Text] [Related]
23. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
Park S; Gatchalian KK; Oh H
Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
[TBL] [Abstract][Full Text] [Related]
24. The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults.
Wang Q; Ning J; Chen Y; Li B; Shi L; He T; Zhang F; Chen X; Zhai A; Wu C
Front Microbiol; 2022; 13():1008420. PubMed ID: 36406456
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study.
Petrović V; Vuković V; Patić A; Marković M; Ristić M
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679901
[TBL] [Abstract][Full Text] [Related]
26. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
27. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang W; Zhang W; Li N; Xie Z; Zhu X; Ding L; You W; Zhao Y; Zhao J; Huang L; Shi X; Yang Y; Xu G; Wang W; Liu P; Ma M; Qiao Y; Zhao S; Chai J; Li Q; Fu H; Xu Y; Zheng X; Guo W; Yang X
Lancet Infect Dis; 2022 Feb; 22(2):196-208. PubMed ID: 34536349
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study.
Ai J; Zhang Y; Zhang H; Zhang Q; Fu Z; Lin K; Song J; Zhao Y; Fan M; Wang H; Zhou Y; Chen X; Qiu C; Zhang W
Emerg Microbes Infect; 2022 Dec; 11(1):639-647. PubMed ID: 35034582
[TBL] [Abstract][Full Text] [Related]
30. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
31. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection.
Hueda-Zavaleta M; Gómez de la Torre JC; Cáceres-Del Aguila JA; Muro-Rojo C; De La Cruz-Escurra N; Arenas Siles D; Minchón-Vizconde D; Copaja-Corzo C; Bardales-Silva F; Benites-Zapata VA; Rodriguez-Morales AJ
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455251
[TBL] [Abstract][Full Text] [Related]
33. Anti-SARS-Cov-2 S-RBD IgG Formed after BNT162b2 Vaccination Can Bind C1q and Activate Complement.
Abu-Humaidan AHA; Ahmad FM; Awajan D; Jarrar RF; Alaridah N
J Immunol Res; 2022; 2022():7263740. PubMed ID: 36573216
[TBL] [Abstract][Full Text] [Related]
34. BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
Bao Y; He L; Miao B; Zhong Z; Lu G; Bai Y; Liang Q; Ling Y; Ji P; Su B; Zhao GP; Wu H; Zhang W; Wang Y; Chen Y; Xu J
Vaccine; 2023 May; 41(20):3258-3265. PubMed ID: 37085449
[TBL] [Abstract][Full Text] [Related]
35. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection.
Jeewandara C; Aberathna IS; Dayarathna S; Nimasha T; Ranasinghe T; Jayamali J; Kamaladasa A; Karunanada M; Perera L; Ogg GS; Malavige GN
PLoS One; 2022; 17(10):e0274845. PubMed ID: 36227884
[TBL] [Abstract][Full Text] [Related]
37. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
[TBL] [Abstract][Full Text] [Related]
38. Investigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population: A prospective observational study.
Hasan Z; Masood KI; Qaiser S; Khan E; Hussain A; Ghous Z; Khan U; Yameen M; Hassan I; Nasir MI; Qazi MF; Memon HA; Ali S; Baloch S; Bhutta ZA; Veldhoen M; Pedro Simas J; Mahmood SF; Ghias K; Hussain R
Health Sci Rep; 2023 Sep; 6(9):e1521. PubMed ID: 37692793
[TBL] [Abstract][Full Text] [Related]
39. Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV.
Liu WD; Pang MW; Wang JT; Sun HY; Huang YS; Lin KY; Wu UI; Li GC; Liu WC; Su YC; He PC; Lin CY; Yeh CY; Cheng YC; Yao Y; Chen YT; Wu PY; Chen LY; Luo YZ; Chang HY; Sheng WH; Hsieh SM; Chang SY; Hung CC; Chang SC
J Virus Erad; 2022 Dec; 8(4):100308. PubMed ID: 36531082
[TBL] [Abstract][Full Text] [Related]
40. Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine.
Mahmoud S; Ganesan S; Sharif-Askari NS; Cantarutti F; Wilson H; Ogrodzki P; Halwani R; Alkaabi N; Zaher WA
Curr Med Res Opin; 2022 Dec; 38(12):2069-2075. PubMed ID: 36274640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
